Akari Therapeutics (United Kingdom)

Recent papers from Akari Therapeutics (United Kingdom)

1. Combination synergy of spliceosome modulator ADC with a K-Ras inhibitor in K-Ras –mutated pancreatic cancers.Journal of Clinical Oncology · 2026
2. Clinical severity classes in COVID-19 pneumonia have distinct immunological profiles, facilitating risk stratification by machine learningFrontiers in Immunology · 2023
3. Immunopathology of terminal complement activation and complement C5 blockade creating a pro‐survival and organ‐protective phenotype in traumaBritish Journal of Pharmacology · 2022
4. Evaluation of Nomacopan for Treatment of Bullous PemphigoidJAMA Dermatology · 2022
5. Votucalis, a Novel Centrally Sparing Histamine-Binding Protein, Attenuates Histaminergic Itch and Neuropathic Pain in MiceFrontiers in Pharmacology · 2022
6. Immune-Mediated Retinal Vasculitis in Posterior Uveitis and Experimental Models: The Leukotriene (LT)B4-VEGF AxisCells · 2021
7. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid diseaseJCI Insight · 2019
8. Structural basis of cholesterol binding by a novel clade of dendritic cell modulators from ticksScientific Reports · 2017
9. Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac functionBasic Research in Cardiology · 2017
10. Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsisJournal of Intensive Care · 2017